Patients
chemotherapy-induced peripheral neuropathy
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
Fifty-eight patients were screened, 57 were enrolled, and 52 received at least one dose of study drug (FAS) (Fig. Patient disposition. The per protocol set (PPS) comprised 30 patients, after exclusion of 22 patients from the full analysis set (FAS) for violations of protocol (study drug not administered in compliance with the Japanese package insert of mirogabalin, such as not at twice-daily dosage and not at an effective dosage, Patient baseline characteristics are summarized in Table Baseline demographic and clinical characteristics of patients with chemotherapy-induced peripheral neuropathy in the MiroCIP interventional study (full analysis set)


